Publications

Add filters (0)

217 results

Viewing results for fatty

Basement membrane repair response biomarker PRO-C4 predicts progression in idiopathic pulmonary fibrosis: analysis of the PFBIO and PROFILE cohorts.

November 14, 2025

Thorax

Abstract BACKGROUND Idiopathic pulmonary fibrosis (IPF) is characterised by damage to the epithelial layer, closely associated with the alveolar basement membrane (BM). We aimed to investigate how type IV collagen (COL4) in the BM changes with the progression of IPF. METHODS COL4 synthesis (PRO-C4) was detected in blood by the nordicPRO-C4 biomarker in patients with […]

Read publication

MetALD: Diagnosis and Prognosis With Non-Invasive Tests.

November 1, 2025

Aliment Pharmacol Ther

Abstract BACKGROUND Non-invasive tests (NITs) are central to diagnosing and stratifying risk in steatotic liver disease (SLD). However, it remains unclear whether guideline-recommended NIT cut-offs apply to metabolic and alcohol-related liver disease (MetALD). AIM Evaluate the diagnostic and prognostic performance of five NITs in patients with MetALD. METHODS Single-centre study with 423 SLD patients, of […]

Read publication

MetALD: Diagnosis and Prognosis With Non-Invasive Tests.

November 1, 2025

Aliment Pharmacol Ther

Abstract BACKGROUND Non-invasive tests (NITs) are central to diagnosing and stratifying risk in steatotic liver disease (SLD). However, it remains unclear whether guideline-recommended NIT cut-offs apply to metabolic and alcohol-related liver disease (MetALD). AIM Evaluate the diagnostic and prognostic performance of five NITs in patients with MetALD. METHODS Single-centre study with 423 SLD patients, of […]

Read publication

MetALD: Diagnosis and Prognosis With Non-Invasive Tests.

November 1, 2025

Aliment Pharmacol Ther

Abstract BACKGROUND Non-invasive tests (NITs) are central to diagnosing and stratifying risk in steatotic liver disease (SLD). However, it remains unclear whether guideline-recommended NIT cut-offs apply to metabolic and alcohol-related liver disease (MetALD). AIM Evaluate the diagnostic and prognostic performance of five NITs in patients with MetALD. METHODS Single-centre study with 423 SLD patients, of […]

Read publication

MetALD: Diagnosis and Prognosis With Non-Invasive Tests.

November 1, 2025

Aliment Pharmacol Ther

Abstract BACKGROUND Non-invasive tests (NITs) are central to diagnosing and stratifying risk in steatotic liver disease (SLD). However, it remains unclear whether guideline-recommended NIT cut-offs apply to metabolic and alcohol-related liver disease (MetALD). AIM Evaluate the diagnostic and prognostic performance of five NITs in patients with MetALD. METHODS Single-centre study with 423 SLD patients, of […]

Read publication

MetALD: Diagnosis and Prognosis With Non-Invasive Tests.

November 1, 2025

Aliment Pharmacol Ther

Abstract BACKGROUND Non-invasive tests (NITs) are central to diagnosing and stratifying risk in steatotic liver disease (SLD). However, it remains unclear whether guideline-recommended NIT cut-offs apply to metabolic and alcohol-related liver disease (MetALD). AIM Evaluate the diagnostic and prognostic performance of five NITs in patients with MetALD. METHODS Single-centre study with 423 SLD patients, of […]

Read publication

Serum markers of fibroinflammatory activity PRO-C3 and CPa9-HNE are associated with liver-related outcomes in patients with Chronic Hepatitis C.

October 31, 2025

J Infect Dis

Abstract BACKGROUND Chronic hepatitis C (CHC) infection remains a global health burden, contributing to the risk of long-term complications such as progressive fibrosis, cirrhosis, and hepatocellular carcinoma, particularly in undiagnosed or untreated individuals. Novel biomarkers for the assessment of disease progression and prognosis are required for fibroinflammatory chronic liver disease. Our study population from the […]

Read publication

Biomarkers of Extracellular Matrix Remodelling Are Linked to Severity and Outcome of Advanced Chronic Liver Disease.

October 12, 2025

Aliment Pharmacol Ther

Abstract BACKGROUND Extracellular matrix (ECM) remodelling in advanced chronic liver disease (ACLD) is characterised by hepatic fibrosis and (sinusoidal) basement membrane development contributing to portal hypertension (PH) and clinical complications. METHODS Patients with stable ACLD (n = 232) undergoing hepatic venous pressure gradient (HVPG) measurement were included. Blood biomarkers reflecting fibrosis formation (PRO-C3, PRO-C6, PRO-C4 and PRO-C18L) […]

Read publication

Differential Effects of Antifibrotic Treatment on Outcome Prediction via Serial Matrix Metalloproteinase-Degraded C-Reactive Protein Neoepitope Levels in Idiopathic Pulmonary Fibrosis.

September 29, 2025

Chest

Abstract BACKGROUND Idiopathic pulmonary fibrosis (IPF) is characterized by an increase in proteolytic enzymes, including matrix metalloproteinases that degrade the extracellular matrix and markers of localized inflammation. Protein fragments (neoepitopes) are detectable in the circulation. RESEARCH QUESTION Can short-term trajectories of neoepitopes after initiation of antifibrotic treatment predict therapy-related outcomes, including mortality, in patients with […]

Read publication

Multi-omic spatial profiling reveals the unique SARS-CoV-2 lung microenvironment and collagen VI as a predictive biomarker in severe COVID-19.

September 1, 2025

Eur Respir J

Abstract BACKGROUND While coronavirus disease 2019 (COVID-19) is primarily a respiratory infection, few studies have characterised the immune response to COVID-19 in lung tissue. We sought to understand the pathogenic role of microenvironmental interactions and the extracellular matrix in post-mortem COVID-19 lung using an integrative multi-omic approach. METHODS Post-mortem formalin-fixed paraffin-embedded lung tissue from fatal […]

Read publication